Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-09

Clinical Trial Update: Safety and Efficacy of IBI306 in HeFH Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on IBI306 in patients with heterozygous familial hypercholesterolemia assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBI306

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Heterozygous Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED